Results 1 to 10 of about 24,793 (292)

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study [PDF]

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +3 more sources

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance

EMBO Molecular Medicine, 2019
Due to compromised homologous recombination (HR) repair, BRCA1‐ and BRCA2‐mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression.
Eliana MC Tacconi, Sophie Badie, Giuliana De Gregoriis, Timo Reisländer, Xianning Lai, Manuela Porru, Cecilia Folio, John Moore, Arnaud Kopp, Júlia Baguña Torres, Deborah Sneddon, Marcus Green, Simon Dedic, Jonathan W Lee, Ankita Sati Batra, Oscar M Rueda, Alejandra Bruna, Carlo Leonetti, Carlos Caldas, Bart Cornelissen, Laurent Brino, Anderson Ryan, Annamaria Biroccio, Madalena Tarsounas   +23 more
doaj   +3 more sources

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects

Journal for ImmunoTherapy of Cancer, 2023
Background Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.Methods We ...
Tyler Curiel, Yilun Deng, Aravind Kancharla, Myrna Garcia, Haiyan Bai, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Anand V R Kornepati, Jose R Conejo-Garcia, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari   +13 more
doaj   +2 more sources

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases [PDF]

Biomedicines
Background/Objectives: Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks.
Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda, Karla Mišura-Jakobac, Jasminka Sinčić-Petričević, Sabina Novaković-Coha, Davor Galušić, Hrvoje Holik, Toni Valković, Dubravka Županić-Krmek, Ida Hude-Dragičević, Vibor Milunović, Vlatko Pejša   +12 more
doaj   +2 more sources

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn   +15 more
doaj   +2 more sources

Chlorambucil-Iron Oxide Nanoparticles as a Drug Delivery System for Leukemia Cancer Cells

International Journal of Nanomedicine, 2021
Samer Hasan Hussein-Al-Ali,1,2 Mohd Zobir Hussein,3 Saifullah Bullo,3 Palanisamy Arulselvan4 1Faculty of Pharmacy, Isra University, Amman, 11622, Jordan; 2Department of Chemistry, Faculty of Science, Isra University, Amman, 11622, Jordan; 3Materials ...
Hussein-Al-Ali SH, Hussein MZ, Bullo S, Arulselvan P   +3 more
doaj   +2 more sources

Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune-Mediated Thrombocytopenia. [PDF]

J Vet Intern Med
ABSTRACT A 2‐year‐old female spayed British Shorthair cat was diagnosed with immune‐mediated thrombocytopenia (ITP) after presenting with a 3‐week history of gastrointestinal bleeding and anemia. Treatment with an immunosuppressive dose of glucocorticoids was initiated, but relapse occurred within 3 weeks.
Kennils JM, Wilson HE.
europepmc   +2 more sources

Treatment outcomes of dogs with transitional cell carcinoma [PDF]

Frontiers in Veterinary Science
Transitional cell carcinoma (TCC) is the most prevalent cancer of the urinary tract in dogs. The prognosis is often poor, and the optimal standard treatment has not been established. The objectives of this study were to (1) describe the clinical outcomes
Ka To Chu, Omid Nekouei, Antonio Giuliano, Antonio Giuliano   +3 more
doaj   +2 more sources

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia. [PDF]

EJHaem
ABSTRACT Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects. Methods We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation.
Heyman B, Choi M, Kipps TJ.
europepmc   +2 more sources

Organising Pneumonia in a Patient Following Obinutuzumab for Follicular Lymphoma. [PDF]

Respirol Case Rep
We present a patient with follicular lymphoma, treated with obinutuzumab who subsequently developing organising pneumonia. The case highlights newer generation of culprits causing pulmonary complications and the importance of vigilant imaging survey and timely treatment to prevent fibrotic progression in these patients.
Nanda V, Ellis H, Bandara H.
europepmc   +2 more sources